[go: up one dir, main page]

AR026745A1 - Composiciones de eplerenona nanoparticulada - Google Patents

Composiciones de eplerenona nanoparticulada

Info

Publication number
AR026745A1
AR026745A1 ARP000106469A ARP000106469A AR026745A1 AR 026745 A1 AR026745 A1 AR 026745A1 AR P000106469 A ARP000106469 A AR P000106469A AR P000106469 A ARP000106469 A AR P000106469A AR 026745 A1 AR026745 A1 AR 026745A1
Authority
AR
Argentina
Prior art keywords
eplerenone
nanoparticulated
compositions
microm
composition
Prior art date
Application number
ARP000106469A
Other languages
English (en)
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of AR026745A1 publication Critical patent/AR026745A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se provee una composicion farmacéutica que comprende eplerenona en la forma de un particulado solido, donde por lo menos un 90% de las partículas deeplerenona son menores que aproximadamente 15 microm, por ejemplo de 0,01 a 1 microm aproximadamente, de diámetro. La composicion se puede adaptar para laadministracion por vía oral, por ejemplo como una tableta o cápsula que comprende eplerenona, en una cantidad de dosificacion unitaria de 10 a 100 mgaproximadamente y uno o varios excipientes.
ARP000106469A 1999-12-08 2000-12-06 Composiciones de eplerenona nanoparticulada AR026745A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16965899P 1999-12-08 1999-12-08
US20898100P 2000-06-02 2000-06-02

Publications (1)

Publication Number Publication Date
AR026745A1 true AR026745A1 (es) 2003-02-26

Family

ID=26865266

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000106469A AR026745A1 (es) 1999-12-08 2000-12-06 Composiciones de eplerenona nanoparticulada

Country Status (13)

Country Link
US (2) US20020006919A1 (es)
EP (1) EP1175220B1 (es)
AR (1) AR026745A1 (es)
AT (1) ATE293977T1 (es)
AU (1) AU1756201A (es)
CO (1) CO5251419A1 (es)
DE (1) DE60019741T2 (es)
DK (1) DK1175220T3 (es)
ES (1) ES2240209T3 (es)
HK (1) HK1039897A1 (es)
PE (1) PE20010910A1 (es)
PT (1) PT1175220E (es)
WO (1) WO2001041770A2 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
BRPI0206641B8 (pt) 2001-01-26 2021-05-25 Merck Sharp & Dohme uso de um inibidor da absorção de esteróis
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
SK288217B6 (sk) 2001-01-26 2014-08-05 Merck Sharp & Dohme Corp. Zmes, terapeutická kombinácia, farmaceutický prostriedok a ich použitie
GB0114532D0 (en) * 2001-06-14 2001-08-08 Jagotec Ag Novel compositions
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
DE60216300T2 (de) 2001-09-21 2007-06-28 Schering Corp. Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
DE60222160T2 (de) * 2001-10-12 2008-06-12 Elan Pharma International Ltd., Athlone Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung
US6455557B1 (en) * 2001-11-28 2002-09-24 Elan Pharmaceuticals, Inc. Method of reducing somnolence in patients treated with tizanidine
US20040220240A1 (en) * 2001-11-28 2004-11-04 Pellegrini Cara A. Method of increasing the extent of absorption of tizanidine
DE10164510A1 (de) * 2001-12-20 2003-07-10 Schering Ag Orale Fludara reinst Formulierung mit schneller Freisetzung des Wirkstoffes
US7008979B2 (en) 2002-04-30 2006-03-07 Hydromer, Inc. Coating composition for multiple hydrophilic applications
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
AU2003291719A1 (en) 2002-11-06 2004-06-03 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
JP2006511525A (ja) * 2002-12-13 2006-04-06 ヤゴテック アーゲー ナノ粒子状スピロノラクトン局所製剤
CN1756756A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
CA2517573C (en) 2003-03-07 2011-12-06 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
ES2311806T3 (es) * 2003-03-07 2009-02-16 Schering Corporation Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
WO2007012960A1 (en) * 2005-07-29 2007-02-01 Glenmark Pharmaceuticals Limited Pharmaceutical compositions of eplerenone
US20070128270A1 (en) * 2005-11-10 2007-06-07 Wyeth Pharmaceutical formulations containing 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl)amino]-n-methyl-1-benzofuran-3-carboxamide and method of making the same
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
WO2008011051A1 (en) * 2006-07-17 2008-01-24 Liquidia Technologies, Inc. Nanoparticle fabrication methods, systems, and materials
WO2008021666A2 (en) * 2006-08-18 2008-02-21 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
US20100055459A1 (en) * 2006-08-30 2010-03-04 Liquidia Technologies, Inc. Nanoparticles Having Functional Additives for Self and Directed Assembly and Methods of Fabricating Same
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US20100086586A1 (en) * 2006-12-21 2010-04-08 Brett Antony Mooney Pharmaceutical Composition
WO2009010837A2 (en) * 2007-07-13 2009-01-22 Pfizer Products Inc. Nanoparticles comprising a non-ionizable polymer and an anionic cellulosic polymer
US9082409B2 (en) * 2008-08-28 2015-07-14 Avaya Inc. Binary-caching for XML documents with embedded executable code
EP2201977A1 (de) * 2008-12-23 2010-06-30 Siegfried Generics International AG Dosiervorrichtung zur Erzeugung eines Gasstromes mit einem in diesem fein verteilten Wirkstoff
EP2385824A2 (en) * 2009-01-06 2011-11-16 Pharmanova, Inc. Nanoparticle pharmaceutical formulations
US9345848B2 (en) 2009-10-20 2016-05-24 Sima Patent Ve Lisanslama Hizmetleri Ltd. Sti. Dry powder inhaler
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
TR201007653A2 (tr) * 2010-09-20 2012-04-24 Bi̇lgi̇ç Mahmut Eplerenon içeren farmasötik kompozisyon
US9849255B2 (en) 2011-11-25 2017-12-26 Mahmut Bilgic Inhalation device
CN103263398B (zh) * 2013-06-06 2014-05-14 山东罗欣药业股份有限公司 一种头孢地尼组合物胶囊及其制备方法
USD744087S1 (en) 2013-10-01 2015-11-24 Mahmut Bilgic Dry powder inhaler
WO2015065547A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
CN109925293B (zh) * 2019-03-15 2022-02-01 南京卡文迪许生物工程技术有限公司 依普利酮口服固体制剂及其制备方法
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US11969502B2 (en) 2019-12-09 2024-04-30 Nicoventures Trading Limited Oral products
US12310959B2 (en) 2019-12-09 2025-05-27 Nicoventures Trading Limited Oral compositions with reduced water content
US11872231B2 (en) 2019-12-09 2024-01-16 Nicoventures Trading Limited Moist oral product comprising an active ingredient
US12439952B2 (en) 2019-12-09 2025-10-14 Nicoventures Trading Limited Moist oral compositions
US11793230B2 (en) 2019-12-09 2023-10-24 Nicoventures Trading Limited Oral products with improved binding of active ingredients
US12433321B2 (en) 2019-12-09 2025-10-07 Nicoventures Trading Limited Oral composition with beet material
US11617744B2 (en) 2019-12-09 2023-04-04 Nico Ventures Trading Limited Moist oral compositions
US12439949B2 (en) 2019-12-09 2025-10-14 Nicoventures Trading Limited Oral compositions with reduced water activity
US11826462B2 (en) 2019-12-09 2023-11-28 Nicoventures Trading Limited Oral product with sustained flavor release
MX2023015529A (es) 2021-06-25 2024-03-05 Nicoventures Trading Ltd Productos orales y metodo de fabricacion.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI77669C (fi) * 1983-04-13 1989-04-10 Ciba Geigy Ag 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat.
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)

Also Published As

Publication number Publication date
DE60019741T2 (de) 2006-03-02
ATE293977T1 (de) 2005-05-15
EP1175220B1 (en) 2005-04-27
PT1175220E (pt) 2005-07-29
CO5251419A1 (es) 2003-02-28
WO2001041770A2 (en) 2001-06-14
WO2001041770A3 (en) 2001-11-22
EP1175220A2 (en) 2002-01-30
HK1039897A1 (zh) 2002-05-17
US20020006919A1 (en) 2002-01-17
AU1756201A (en) 2001-06-18
US20030212053A1 (en) 2003-11-13
ES2240209T3 (es) 2005-10-16
DK1175220T3 (da) 2005-08-29
PE20010910A1 (es) 2001-09-10
DE60019741D1 (de) 2005-06-02

Similar Documents

Publication Publication Date Title
AR026745A1 (es) Composiciones de eplerenona nanoparticulada
ATE345782T1 (de) Dosierungsformen enthaltend geschmacksmaskierten wirkstoffen
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
CL2019000209A1 (es) Formulación novedosa administrable por la vía oral.
UY26306A1 (es) Composición para la dosificación oral, de disolución instantanea
TR200100931T2 (tr) Yeni sürekli salınımlı oral formülasyonlar
NO330947B1 (no) Anvendelse av farmasoytiske sammensetninger som inneholder okskarbazepin, i fastende tilstand
MXPA05007643A (es) Metodo para producir una forma farmaceutica oral con desintegracion inmediata y liberacion de ingrediente activo.
UA42061C2 (uk) Фармацевтична композиція для перорального введення, що містить інгібітори протонного насоса
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
HUP0004966A3 (en) Pharmaceutical composition for oral administration in the form of matrix tablet enabling the prolonged release of trimetazidine
BG102857A (en) Antimycotic substance-containing and acetate buffer-containing compositions
NO20030897D0 (no) Fremgangsmåte for fremstilling av farmasöytiske sammensetninger for anvendelse med blöte gelatin formuleringer
AR022589A1 (es) UNA CÁPSULA QUE COMPRENDE UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL, UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL Y EL USO PARA LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DEL CÁNCER
IT1170215B (it) Composizione farmaceutica per il trattamento di stati di insufficienza renale acuta
DE69923336D1 (de) Oral anzuwendende buprenorphinhaltige arzneimittel
ECSP003807A (es) Composiciones valdecoxib
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
ID28510A (id) Formulasi oral yang baru untuk agonis atau antagonis 5-ht4
MXPA06000332A (es) Nueva composicion farmaceutica solida que comprende amisulprida.
ES2099021B1 (es) Composicion farmaceutica que tiene actividad analgesica.
EA200701923A1 (ru) Лекарственная форма для перорального введения витамина
ES2150404T3 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
TR200200683T2 (tr) Oral kontrollü salıverme formülasyonları.
HRP20020258B1 (hr) Farmaceutska kombinacija etinilestradiola i drospirenona za upotrebu kao kontracepcijskog sredstva

Legal Events

Date Code Title Description
FB Suspension of granting procedure